Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,871 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate Control Clear all
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

NCT02324842
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Liraglutide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

NCT01274637
View directory record Official record
Conditions
Venous Thromboembolism, Postpartum
Interventions
Dalteparin Sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Charlottesville, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

NCT01137812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Citicoline for Bipolar 1 Disorder and Cocaine Dependence

NCT00619723
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence
Interventions
Citicoline, Placebo, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Naltrexone for Pathological Gambling

NCT01057862
View directory record Official record
Conditions
Pathological Gambling
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Middletown, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 28, 2026, 4:01 PM EDT
Withdrawn Phase 3 Interventional

Acetaminophen Randomized Controlled Trial

NCT02737124
View directory record Official record
Conditions
Post Operative Pain
Interventions
Acetaminophen, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional

Evaluation of the Impact of Water Access and Promotion in Parks on Beverage Intake

NCT03889561
View directory record Official record
Conditions
Obesity
Interventions
Drink Tap
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
1,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 28, 2026, 4:01 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670
View directory record Official record
Conditions
Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

NCT02477423
View directory record Official record
Conditions
Premature Birth of Newborn, Enterocolitis, Necrotizing
Interventions
Ampicillin, Gentamicins, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 6 Hours
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Full-fat or Low-fat Dairy Foods on Insulin Sensitivity, RBC FA's and Other Markers of Metabolic Health

NCT04999462
View directory record Official record
Conditions
Overweight and Obesity, Elevated Triglycerides
Interventions
Full-fat fermented dairy, Low-fat fermented dairy, Non-dairy, non-fermented foods
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
4
States / cities
Miami Gardens, Florida • Chicago, Illinois • Gurnee, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

NCT00383786
View directory record Official record
Conditions
PTSD
Interventions
NK1 Antagoist (GR205171), Psychophysiology (Trauma Script), Psychophysiology (Verbal Threat), Psychophysiology (Fear Conditioning), Psychophysiology (Affective Modulation), Psychophysiology (Heart rate variability), Lumbar Puncture, 24-hour plasma sampling, MRI
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

NCT00001042
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Fampridine-SR in Multiple Sclerosis

NCT00127530
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multiple Health Behavior Change Intervention for Overweight and Obese Smokers

NCT05136430
View directory record Official record
Conditions
Smoking Cessation, Obesity
Interventions
Self-Regulation strategies + large changes (SR), Healthy Lifestyle Education (LE), Smoking Cessation Treatment
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 28, 2026, 4:01 PM EDT
Not listed Not applicable Interventional

FreeStyle Libre 2 Discharge Trial

NCT05822232
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypoglycemia
Interventions
FreeStyle Libre 2 CGM, FreeStyle Libre Pro blinded CGM, FreeStyle Precision Neo blood glucose meter
Device
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 28, 2026, 4:01 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 28, 2026, 4:01 PM EDT
Terminated Not applicable Interventional

Effects of a Three-Month Low Calorie Diet Weight Loss Intervention on Knee Replacement Outcomes

NCT04015011
View directory record Official record
Conditions
Obesity
Interventions
LCD Intervention
Combination Product
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional

Project IMPACT: CHW Intervention

NCT03159533
View directory record Official record
Conditions
Hypertension
Interventions
CHW Intervention, Wait List Control Group
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 28, 2026, 4:01 PM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 28, 2026, 4:01 PM EDT
Terminated Not applicable Interventional Results available

Glucose Control In Hematopoetic Stem Cell Transplant

NCT00582036
View directory record Official record
Conditions
Hyperglycemia, Hematopoietic Stem Cell Transplantation
Interventions
Regular Insulin, Deployment of the MiniMed Paradigm monitoring device
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Atomoxetine and Huntington's Disease

NCT00368849
View directory record Official record
Conditions
Huntington Disease, Chorea
Interventions
atomoxetine, Matching Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 28, 2026, 4:01 PM EDT